Identifying colorectal cancer caused by biallelic MUTYH pathogenic variants using tumor mutational signatures
-
Published:2022-06-06
Issue:1
Volume:13
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Georgeson PeterORCID, Harrison Tabitha A., Pope Bernard J.ORCID, Zaidi Syed H., Qu Conghui, Steinfelder Robert S., Lin Yi, Joo Jihoon E., Mahmood Khalid, Clendenning Mark, Walker Romy, Amitay Efrat L.ORCID, Berndt Sonja I., Brenner Hermann, Campbell Peter T., Cao Yin, Chan Andrew T.ORCID, Chang-Claude JennyORCID, Doheny Kimberly F.ORCID, Drew David A., Figueiredo Jane C., French Amy J., Gallinger Steven, Giannakis MariosORCID, Giles Graham G.ORCID, Gsur AndreaORCID, Gunter Marc J., Hoffmeister MichaelORCID, Hsu Li, Huang Wen-YiORCID, Limburg Paul, Manson JoAnn E., Moreno VictorORCID, Nassir Rami, Nowak Jonathan A., Obón-Santacana Mireia, Ogino ShujiORCID, Phipps Amanda I., Potter John D.ORCID, Schoen Robert E.ORCID, Sun WeiORCID, Toland Amanda E.ORCID, Trinh Quang M.ORCID, Ugai Tomotaka, Macrae Finlay A., Rosty Christophe, Hudson Thomas J.ORCID, Jenkins Mark A.ORCID, Thibodeau Stephen N., Winship Ingrid M., Peters UlrikeORCID, Buchanan Daniel D.ORCID
Abstract
AbstractCarriers of germline biallelic pathogenic variants in the MUTYH gene have a high risk of colorectal cancer. We test 5649 colorectal cancers to evaluate the discriminatory potential of a tumor mutational signature specific to MUTYH for identifying biallelic carriers and classifying variants of uncertain clinical significance (VUS). Using a tumor and matched germline targeted multi-gene panel approach, our classifier identifies all biallelic MUTYH carriers and all known non-carriers in an independent test set of 3019 colorectal cancers (accuracy = 100% (95% confidence interval 99.87–100%)). All monoallelic MUTYH carriers are classified with the non-MUTYH carriers. The classifier provides evidence for a pathogenic classification for two VUS and a benign classification for five VUS. Somatic hotspot mutations KRAS p.G12C and PIK3CA p.Q546K are associated with colorectal cancers from biallelic MUTYH carriers compared with non-carriers (p = 2 × 10−23 and p = 6 × 10−11, respectively). Here, we demonstrate the potential application of mutational signatures to tumor sequencing workflows to improve the identification of biallelic MUTYH carriers.
Funder
Department of Health | National Health and Medical Research Council
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference48 articles.
1. Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020). 2. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013). 3. Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517–525 (2017). 4. Georgeson, P. et al. Tumor mutational signatures in sebaceous skin lesions from individuals with Lynch syndrome. Mol. Genet. Genom. Med. 7, e00781 (2019). 5. Pilati, C. et al. Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. J. Pathol. 242, 10–15 (2017).
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|